JP2011509237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509237A5 JP2011509237A5 JP2010507751A JP2010507751A JP2011509237A5 JP 2011509237 A5 JP2011509237 A5 JP 2011509237A5 JP 2010507751 A JP2010507751 A JP 2010507751A JP 2010507751 A JP2010507751 A JP 2010507751A JP 2011509237 A5 JP2011509237 A5 JP 2011509237A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hydroxy
- composition according
- alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- -1 prostaglandin compound Chemical class 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 9
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 229910052717 sulfur Chemical group 0.000 claims description 9
- 239000011593 sulfur Chemical group 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 2
- 229920001684 low density polyethylene Polymers 0.000 claims description 2
- 239000004702 low-density polyethylene Substances 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10340308P | 2008-10-07 | 2008-10-07 | |
| US61/103,403 | 2008-10-07 | ||
| PCT/JP2009/067586 WO2010041722A2 (en) | 2008-10-07 | 2009-10-02 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013119810A Division JP2013177446A (ja) | 2008-10-07 | 2013-06-06 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509237A JP2011509237A (ja) | 2011-03-24 |
| JP2011509237A5 true JP2011509237A5 (enExample) | 2011-05-06 |
| JP5320388B2 JP5320388B2 (ja) | 2013-10-23 |
Family
ID=41479177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507751A Active JP5320388B2 (ja) | 2008-10-07 | 2009-10-02 | 医薬組成物 |
| JP2013119810A Pending JP2013177446A (ja) | 2008-10-07 | 2013-06-06 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013119810A Pending JP2013177446A (ja) | 2008-10-07 | 2013-06-06 | 医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100087540A1 (enExample) |
| EP (1) | EP2341894B1 (enExample) |
| JP (2) | JP5320388B2 (enExample) |
| KR (1) | KR101166739B1 (enExample) |
| CN (1) | CN102215817B (enExample) |
| AR (1) | AR073781A1 (enExample) |
| CA (1) | CA2739710A1 (enExample) |
| ES (1) | ES2392221T3 (enExample) |
| TW (1) | TWI403324B (enExample) |
| WO (1) | WO2010041722A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8952051B2 (en) * | 2009-11-05 | 2015-02-10 | Allergan, Inc. | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| KR20130099812A (ko) * | 2010-04-12 | 2013-09-06 | 가부시키가이샤 아루떼꾸 우에노 | 황반 부종을 치료하기 위한 약학적 조성물 |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| CN116144620B (zh) * | 2022-09-14 | 2025-08-12 | 湖南农业大学 | 一种通过解脂耶氏酵母体外催化合成PGF2α的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208256A (en) * | 1990-05-22 | 1993-05-04 | R-Tech Ueno, Ltd. | Treatment of ocular hypertension with a synergistic combination for ocular administration |
| US6770675B2 (en) * | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
| WO2000003736A1 (en) * | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Prostaglandin product |
| AU2002212234A1 (en) * | 2000-09-14 | 2002-03-26 | Novartis Ag | Stable ophthalmic preparation |
| US20040076678A1 (en) * | 2002-08-21 | 2004-04-22 | Sucampo Ag | Opthalmic solution |
| ES2431640T3 (es) * | 2003-08-21 | 2013-11-27 | Sucampo Ag | Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad |
| US20050049311A1 (en) * | 2003-09-03 | 2005-03-03 | Pharmacia & Upjohn Company | Medicinal products comprising prostaglandin compositions and methods of packaging such compositions |
| CA2536874A1 (en) * | 2003-09-05 | 2005-03-17 | Novartis Ag | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives |
| US20050287325A1 (en) * | 2004-06-25 | 2005-12-29 | Pharmacia & Upjohn Company | Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| BRPI0708891A2 (pt) * | 2006-03-13 | 2011-06-28 | R Tech Ueno Ltd | composição aquosa |
| JPWO2008096804A1 (ja) * | 2007-02-07 | 2010-05-27 | テイカ製薬株式会社 | ラタノプロスト含有点眼剤 |
| PT2254549E (pt) * | 2008-03-17 | 2014-01-30 | Alcon Res Ltd | Composições farmacêuticas aquosas que contêm complexos de borato-poliol |
-
2009
- 2009-10-01 US US12/571,672 patent/US20100087540A1/en not_active Abandoned
- 2009-10-02 ES ES09788094T patent/ES2392221T3/es active Active
- 2009-10-02 WO PCT/JP2009/067586 patent/WO2010041722A2/en not_active Ceased
- 2009-10-02 JP JP2010507751A patent/JP5320388B2/ja active Active
- 2009-10-02 EP EP09788094A patent/EP2341894B1/en not_active Not-in-force
- 2009-10-02 CA CA2739710A patent/CA2739710A1/en not_active Abandoned
- 2009-10-02 KR KR1020097026736A patent/KR101166739B1/ko not_active Expired - Fee Related
- 2009-10-02 CN CN2009801458654A patent/CN102215817B/zh not_active Expired - Fee Related
- 2009-10-06 TW TW098133793A patent/TWI403324B/zh not_active IP Right Cessation
- 2009-10-07 AR ARP090103851A patent/AR073781A1/es unknown
-
2013
- 2013-06-06 JP JP2013119810A patent/JP2013177446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0308135B1 (en) | Ocular hypotensive agents | |
| ES2966094T3 (es) | Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos | |
| CA2377661A1 (en) | Use of fatty acid derivative for the treatment of external secretion disorders | |
| KR20100092909A (ko) | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2011509237A5 (enExample) | ||
| TWI302100B (en) | Composition for treating drug-induced constipation | |
| JP2011516511A5 (enExample) | ||
| JP2004527567A5 (enExample) | ||
| CA2767083A1 (en) | Bicyclic compound and use thereof for medical purposes | |
| JP2006513232A5 (enExample) | ||
| RU2018113296A (ru) | Фармацевтическая композиция, содержащая 11-дезокси-простагландиновое соединение и способ стабилизации этого соединения | |
| JP2004529960A5 (enExample) | ||
| US20130310438A1 (en) | Bicyclic compound and use thereof for medical purposes | |
| US8669284B2 (en) | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound | |
| RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии | |
| JP2006506381A5 (enExample) | ||
| JP2011513317A5 (enExample) | ||
| JP2010533707A5 (enExample) | ||
| TW200944210A (en) | Cathartic composition | |
| JP2014511825A5 (enExample) | ||
| JP2004519412A5 (enExample) | ||
| JP2008528440A5 (enExample) | ||
| JP2019534296A5 (enExample) | ||
| CN104530127B (zh) | 一种淫羊藿苷衍生物及其使用方法和用途 |